Highly attenuated vaccinia virus DIs as a potential SARS vaccine.
Ishii
Koji
K
National Institute of Infectious Diseases, Tokyo, Japan.
Hasegawa
Hideki
H
Nagata
Noriyo
N
Mizutani
Tetsuya
T
Morikawa
Shigeru
S
Tashiro
Masato
M
Suzuki
Tetsuro
T
Taguchi
Fumihiro
F
Takemori
Toshitada
T
Miyamura
Tatsuo
T
Tsunetsugu-Yokota
Yasuko
Y
D000818:Animals; D000914:Antibodies, Viral / Q000737:chemistry; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000737:chemistry; D045473:Severe acute respiratory syndrome-related coronavirus / Q000235:genetics*; D045169:Severe Acute Respiratory Syndrome / Q000235:genetics* / Q000517:prevention & control*; D014616:Vaccinia virus / Q000378:metabolism*; D014759:Viral Envelope Proteins; D014765:Viral Vaccines / Q000494:pharmacology*
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; D014765:Viral Vaccines